Unverified60% confidenceFactExact time
Lecanemab only slowed the rate of cognitive decline by approximately 27% over an 18-month trial, and its clinical significance remains controversial.
2
Sources
60%
Confidence
Long-term
Relevance
7/7/2026
First Seen
Sources
Can a Nasal Spray Reverse Brain Aging? A Deep Dive into the Latest Neuroscience Breakthrough
hackernewshackernews7/4/2026
Related Claims
Unverified已有研究发现早年切除迷走神经的患者帕金森病发病率显著降低66% similarUnverified21.2% is a relative reduction rather than an absolute one, meaning the new version eliminates approximately one-fifth of the failures relative to the earlier version's failure rate baseline.64% similarUnverifiedAfter applying DA, Gemma-4-31B reduced attention tokens by 52.0%, with an accuracy drop of only 1.27 percentage points.63% similarUnverifiedThe small model pair halves the download size and reduces peak memory by about 35% compared with the original model pair, but in this trial the full turn was actually slower.63% similarUnverifiedIn real-environment A/B testing, the post-trained checkpoint reduced the tool-call failure rate by 21.2% relatively compared to the earlier version.62% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/171960API
curl https://kongchang.com/api/v1/knowledge/claims/171960MCP
get_claim(id=171960)